Renal involvement in progressive systemic sclerosis: prolonged survival with aggressive antihypertensive management.
D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D006332:Cardiomegaly / Q000150:complications / Q000209:etiology; D004077:Digoxin / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005665:Furosemide / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D006830:Hydralazine / Q000008:administration & dosage / Q000627:therapeutic use; D006974:Hypertension, Malignant / Q000188:drug therapy / Q000209:etiology*; D006977:Hypertension, Renal / Q000188:drug therapy / Q000209:etiology*; D007674:Kidney Diseases / Q000150:complications*; D008750:Methyldopa / Q000008:administration & dosage / Q000627:therapeutic use; D008914:Minoxidil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011433:Propranolol / Q000008:administration & dosage / Q000627:therapeutic use; D012595:Scleroderma, Systemic / Q000150:complications*; D013997:Time Factors
D000959:Antihypertensive Agents; D006830:Hydralazine; D008750:Methyldopa; D008914:Minoxidil; D004077:Digoxin; D005665:Furosemide; D011433:Propranolol